|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Assets, Current | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Marketable securities | ||||||||||||||||
| Restricted cash, current | ||||||||||||||||
| Receivable from collaboration partner | ||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||
| Total current assets | ||||||||||||||||
| Restricted cash, non-current | ||||||||||||||||
| Marketable securities, non-current | ||||||||||||||||
| Property and equipment, net | ||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||
| Prepaid research and development expenses and other long-term assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Accounts payable | ||||||||||||||||
| Accrued liabilities | ||||||||||||||||
| Operating lease liabilities, current portion | ||||||||||||||||
| Finance lease liabilities, current portion | ||||||||||||||||
| Contract liability to related party | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||
| Contract liabilities, net of current portion to related party | ||||||||||||||||
| Other non-current liabilities | ||||||||||||||||
| Finance lease liabilities, net of current portion | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Stockholders' equity | ||||||||||||||||
| Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 57,929,325 shares issued and outstanding as of December 31, 2025; 1,000,000,000 shares authorized and 54,293,597 shares issued and outstanding as of December 31, 2024 | ||||||||||||||||
| Additional paid-in capital | ||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||
| Accumulated Deficit | ||||||||||||||||
| Total stockholders' equity | ||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||
Loading...
